Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors

被引:31
|
作者
Schilder, C. M. T. [1 ]
Seynaeve, C. [2 ]
Linn, S. C. [3 ]
Boogerd, W. [4 ,5 ]
Beex, L. V. A. M. [6 ]
Gundy, C. M. [1 ]
Nortier, J. W. R. [7 ]
van de Velde, C. J. H. [8 ]
van Dam, F. S. A. M. [1 ]
Schagen, S. B. [1 ]
机构
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Psychosocial Res & Epidemiol, NL-1066 CX Amsterdam, Netherlands
[2] Dr Daniel Den Hoed Canc Ctr, Dept Med Oncol, Erasmus Med Ctr, NL-3008 AE Rotterdam, Netherlands
[3] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[4] Netherlands Canc Inst, Dept Neurooncol, Amsterdam, Netherlands
[5] Slotervaart Med Ctr, Dept Neurol, Amsterdam, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands
[7] Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands
[8] Leiden Univ, Med Ctr, Dept Surg Oncol, Leiden, Netherlands
关键词
Breast cancer; Postmenopausal; Cognitive function; Neuropsychological testing; Psychological function; Adjuvant systemic treatment; REPRODUCTIVE PERIOD; CHEMOTHERAPY; RISK; IMPAIRMENT; WOMEN; DYSFUNCTION; DEMENTIA; PEOPLE;
D O I
10.1016/j.critrevonc.2009.11.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study aimed to identify medical and psychological predictors for cognitive performance of breast cancer (BC) patients before the start of adjuvant systemic treatment and to compare cognitive performance between BC patients and healthy controls adjusting for medical and psychological variables. Material: 205 postmenopausal BC patients underwent pre-treatment neuropsychological tests and provided medical and psychological data. 124 healthy controls underwent the same assessment. Results: 'Treatment for diabetes mellitus' and/or 'hypertension', 'less hours spent on cognitively stimulating activities', 'fewer days since surgery' and 'more reproductive years' were associated with worse cognitive performance in the BC patients, independent of age and IQ. Cognitive differences between BC patients and healthy controls could partly be explained by the evaluated variables. Conclusion: The results stress the need for adjustment for pre-treatment cognitive differences between study groups, and also indicate that further research into pre-treatment cognitive dysfunction is warranted. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 50 条
  • [1] Cognitive functioning in breast cancer women before receiving a systemic oncologicall treatment (adjuvant chemotherapy or hormone-therapy)
    Rubio, Beatriz
    Sirgo, Agustina
    Guma, Josep
    PSYCHO-ONCOLOGY, 2008, 17 : S21 - S22
  • [2] The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy
    Schilder, Christina M.
    Seynaeve, Caroline
    Linn, Sabine C.
    Boogerd, Willem
    Gundy, Chad M.
    Beex, Louk V.
    van Dam, Frits S.
    Schagen, Sanne B.
    PSYCHO-ONCOLOGY, 2010, 19 (04) : 415 - 422
  • [3] Prevalence of cognitive complaints is not higher in postmenopausal breast cancer patients before adjuvant hormonal therapy compared to healthy controls
    Schilder, C. M.
    van, Dam F.
    Boogerd, W. S.
    Seynaeve, C.
    van de Velde, C. J.
    Nortier, H. W.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S76 - S76
  • [4] Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients
    Gnant, Michael
    BREAST CARE, 2010, 5 (05) : 298 - 304
  • [5] Adjuvant endocrine therapy in postmenopausal breast cancer patients
    Köberle, D
    Thürlimann, B
    BREAST, 2005, 14 (06): : 446 - 451
  • [6] Cognitive Functioning and Psychological Well-being in Breast Cancer Patients on Endocrine Therapy
    Biro, Edit
    Kahan, Zsuzsanna
    Kalman, Janos
    Rusz, Orsolya
    Pakaski, Magdolna
    Irinyi, Tamas
    Kelemen, Gyongyi
    Dudas, Rita
    Drotos, Gergely
    Hamvai, Csaba
    IN VIVO, 2019, 33 (04): : 1381 - 1392
  • [7] Systemic therapy of metastatic breast cancer in postmenopausal patients
    Rose, C
    Lornan, N
    Killander, F
    Kinhult, S
    ADVANCES IN ENDOCRINE THERAPY OF BREAST CANCER, PROCEEDINGS, 2004, : 33 - 46
  • [8] Postmenopausal hormone therapy and its association with breast cancer
    Syal, Arshi
    Aggarwal, Neelam
    JOURNAL OF MID-LIFE HEALTH, 2020, 11 (04) : 187 - 195
  • [9] Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer
    Merriman, John D.
    Sereika, Susan M.
    Brufsky, Adam M.
    McAuliffe, Priscilla F.
    McGuire, Kandace P.
    Myers, Jamie S.
    Phillips, Mary L.
    Ryan, Christopher M.
    Gentry, Amanda L.
    Jones, Lindsay D.
    Bender, Catherine M.
    PSYCHO-ONCOLOGY, 2017, 26 (01) : 44 - 52
  • [10] Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients
    Amir, E.
    Ocana, A.
    Niraula, S.
    Carlsson, L.
    Seruga, B.
    CANCER RESEARCH, 2010, 70